Literature DB >> 32035641

[Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].

Anne Couvelard1, Jean-Yves Scoazec2.   

Abstract

About 5% of gastroenteropancreatic and thoracic neuroendocrine neoplasms (NENs) arise in the context of an inherited tumour syndrome. The two most frequent syndromes are: multiple endocrine neoplasia type 1 (MEN1), associated with a large spectrum of endocrine and non endocrine tumours, including duodenopancreatic, thymic and bronchial NENs, and the von Hippel-Lindau syndrome VHL, associated with pancreatic NENs. Two inherited syndromes have a low incidence of NENs: neurofibromatosis type 1 (NF1), associated with duodenal somatostatinomas, and tuberous sclerosis (TSC), associated with pancreatic NENs. Two rare syndromes have a high incidence of NENs: multiple endocrine neoplasia type 4 (MEN4), with a tumour spectrum similar to that of MEN1, and glucagon cell hyperplasia neoplasia (GCHN), involving only the pancreas. It is likely that other syndromes remain to be characterized, especially in familial small-intestinal NENs. The diagnosis is usually raised because of the suggestive clinical setting: young age at diagnosis, multiple tumours in multiple organs, familial history. Except in VHL and NF1, tumours themselves do not show specific pathological features; they usually are well differentiated and of low histological grade; their prognosis is good, except for MEN1-associated thymic NENs. The most suggestive pathological feature is their combination with various endocrine and/or non endocrine lesions in the adjacent tissue. Pathological examination is important, for a correct diagnosis and for an accurate management of the patients and their families, who must be referred to expert centers.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  MEN1; MEN4; NEM1; NF1; Neuroendocrine neoplasms; Syndrome VHL; TSC; Tumeurs neuroendocrines; VHL syndrome

Mesh:

Year:  2020        PMID: 32035641     DOI: 10.1016/j.annpat.2020.01.002

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  3 in total

Review 1.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 2.  Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.

Authors:  R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2022-08-30       Impact factor: 5.467

Review 3.  Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

Authors:  Benjamin Chevalier; Hippolyte Dupuis; Arnaud Jannin; Madleen Lemaitre; Christine Do Cao; Catherine Cardot-Bauters; Stéphanie Espiard; Marie Christine Vantyghem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-06       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.